Follow us on TwitterTop Story
Novartis, Incyte strike potential $1B deal
Wilmington, DE-based Incyte announced today that it will get a hefty $150 million up front and a $60 million milestone payment on a new licensing deal with Novartis that could be worth more than $1 billion. In one fell swoop, Novartis has added two hematology-oncology drug candidates to its pipeline. Report
Latest News
Also Noted
> Curemark is conducting clinical trials at the Southwest Autism and Resource Center in Phoenix and 11 other sites across the U.S. on a treatment that helps children digest proteins. Story
> Wilmington cancer researchers have received a second round of federal funding to address the disease's unequal burden on minority and underserved groups. New Hanover Regional Medical Center's Zimmer Cancer Center will get nearly $2 million during the next five years from a National Cancer Institute program. Report
> The International Association of Synthetic Biology says that it's close to completing a code of conduct that would cover ethics, biosafety, and biosecurity aspects of gene synthesis. Article
Pharma News
Read more >>Press Releases
- NICE to publish final guidance on topotecan for the treatment of small-cell lung cancer
- Incyte Announces Major Collaboration and License Agreement for Two Hematology-Oncology Programs
- Merck Wins Summary Judgment in Second Federal Bellwether Case Involving FOSAMAX® (alendronate sodium)
- Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
- Oxagen Raises £16 Million
- Clavis Pharma and Clovis Oncology Sign $380 Million Partnership for the Development and Commercialisation of Anti-Cancer Agent C
Latest Comments
Special Report
November's biotech stocks to watch
This month three Canaccord Adams analysts--Adam Cutler, George Farmer and Ritu Baral (bios and photos)--weigh in on five developers that are facing pivotal events. Featured in this issue of On the Radar are Cadence Pharmaceuticals, Micromet, Momenta Pharmaceuticals, Pharmasset, and Protalix BioTherapeutics. Report ⇒Special Report
The 2009 Biotech Graveyard
In the spirit of Halloween FierceBiotech brings you the 2009 Biotech Graveyard; a list of 16 unfortunate companies that didn't have the money, expertise or programs to survive the economic crisis. Report ⇒